Myriad's Q2 Revenues Jump 49 Percent

Myriad attributed a 58 percent jump in molecular diagnostics revenues to an expansion of its sales force and an ongoing DTC campaign.

Full-text access for registered users only. Existing users login here.
New to GenomeWeb? Register here quickly for free access.

Related Stories